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Abstract
Objectives Vesicular drug delivery has become a useful approach for therapeutic administration of 
pharmaceutical compounds. Lipid vesicles have found application in membrane biology, immun-
ology, genetic engineering and theragnostics. This review summarizes topical delivery, specific-
ally dermal/transdermal, ocular and transungual, via these vesicles, including future formulation 
perspectives.
Key findings Liposomes and their subsequent derivatives, viz. niosomes, transferosomes, 
pharmacososmes and ethosomes, form a significant part of vesicular systems that have been suc-
cessfully utilized in treating an array of topical disorders. These vesicles are thought to be a safe 
and effective mode of improving the delivery of lipophilic and hydrophilic drugs.
Summary Several drug molecules are available for topical disorders. However, physicochemical 
properties and undesirable toxicity have limited their efficacy. Vesicular delivery systems have the 
potential to overcome these shortcomings due to properties such as high biocompatibility, simpli-
city of surface modification and suitability as controlled delivery vehicles. However, incorporating 
these systems into environmentally responsive dispersants such as hydrogels, ionic liquids and 
deep eutectic solvents may further enhance therapeutic prowess of these delivery systems. 
Consequently, improved vesicular drug delivery can be achieved by considering combining some 
of these formulation approaches.
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Introduction
Transdermal drug delivery has become an alternative to the trad-
itional oral drug delivery route of administration, in addition to 
offering an alternative to hypodermic injections.[1] Specifically, 
transdermal drug delivery has numerous benefits in comparison 
to oral drug delivery, including bypassing first-pass metabolism, 
which leads to sudden drug metabolism and thus reduced bioavail-
ability.[2] In addition, transdermal delivery avoids the shortcomings 
of hypodermic injections, such as pain at the injection, high dis-
comfort and the severe threat posed by medical waste and disease 
transmission following re-use of needles. Furthermore, transdermal 
drug delivery systems can be self-administered and are inexpensive. 
However, the number of drugs that can be adapted for transdermal 
delivery present as a limitation for this route of administration. 
Over the past decades, technological advancements and innov-
ations within existing drug delivery techniques have led to the 
successful development of drugs with adequate molecular dimen-
sions or delivery systems for efficient transdermal drug delivery. In 
general, transdermal drug delivery is categorized into three gener-
ations (Table 1).[3]
In recent years, vesicular delivery has become a useful approach 
to drug delivery. Lipid vesicles have gained interest in immunology, 
membrane biology, theragnostic and genetic engineering research. 
Vesicles have also been used in biological layer modelling and tar-
geted transport for API.[4–7]
Biological membranes are universal defining structures that sur-
round and compartmentalize all cells and organelles.[1] The lipidic 
bilayer organization is the only feature common to all biological 
membranes. Experimental models explaining the motional dynamics 
and stationary structures of some isolated partitions of biological 
membranes and lipid vesicles are among the various types of ex-
perimental models for understanding bio-membranes. Despite being 
developed for rudimentary research, numerous technological ad-
vancements have surfaced due to using these models.[1] Subsequently, 
they have led to lipid vesicles successfully evolving as suitable vehicles 
for controlled delivery.[1] The advantages and disadvantages of some 
lipid-based vesicular drug delivery system are extensively summar-
ized in Table 2. In addition, formulation strategies to enhance thera-
peutic prowess of vesicular delivery systems, including incorporating 
them into environmentally responsive dispersants such as hydrogels, 
ionic liquids and deep eutectic solvents, are discussed herein.
Significant manuscripts cited in this review and findings from these 
publications are highlighted in Table 3. A  PRISMA flow diagram 
(Figure 1) was used to facilitate the extraction of manuscripts from 
electronic databases. The titles and abstracts of the extracted articles 
were screened for relevance, which led to the elimination of duplicates.





First generation Comprises of transdermal patches for clinical use.
The drug should be of low-molecular weight, 
efficacious at low doses and lipophilic. 
•  High bioavailability as opposed to 
oral bioavailability.
•  No pricking required.
•  Not feasible for drugs 
with high molecular 
weight.
•  Stratum corneum limits 
drug permeability.
•  Not suitable for 
hydrophilic drugs.
Second generation Chemical enhancers are generally utilized effectively 
to improve skin permeability through reversal 
disruption of the stratum corneum to promote 
deeper skin penetration of the drug.
Iontophoresis is another second-generation TDDS 
that does not alter the skin barrier but helps 
in the movement of charged drug through 
electrophoresis.
Non-cavitational ultrasound is another skin 
permeation enhancing method, which is an 
effective second-generation TDDS. This is an 
oscillating wave of pressure at a frequency that is 
intensely high for the human ear. This oscillation 
and the creation of a pressure gradient drive drug 
penetration into the skin while disrupting the 
stratum corneum.
•  Easy penetration of high molecular 
weight drugs through the stratum 
corneum following disruption of 
an ordered bilayer structure of the 
intracellular lipids found within the 
skin layer.
•  Iontophoresis offers high control 
over drug dosing by scaling the 
adequate amount of charge delivered 
to the skin.
•  Provides rapid onset of drug 
response.
•  Non-cavitational ultrasound allows 
for deeper skin penetration of the 
drug
•  Increased risk of skin 
irritation from chemical 
enhancers.
•  Iontophoresis is costly.
•  Non-cavitational 
ultrasound is limited to 
lipophilic and small drug 
molecules.
•  Non-cavitational 
ultrasound can also cause 
damage to deeper skin 
tissues. 
Third generation Third generation systems induce significant 
impacts on the stratum corneum via stronger 
disruption while protecting deeper skin tissues. 
Third generation delivery systems include 
amalgamation of different chemical enhancers, 
biochemical enhancers, electroporation, 
cavitational ultrasound, microneedles, thermal 
ablation and microdermabrasion.
•  Suitable for narrow and specific 
combination of drugs.
•  Proved the highest skin permeability 
without damaging or causing skin 
irritation.
•  Expensive
•  Require technical 
expertise.
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Topical Drug Delivery Systems
Challenges and opportunities for topical drug 
delivery
Dermal/transdermal drug delivery systems
The main challenge for topical applications is the dermal penetration 
of the hard horny layer/stratum corneum (SC), which is the top-most 
layer of the skin.[11] These skin structures act as a rate-limiting step 
for epidermal drug transfer.[12] Additional considerations in topical 
delivery of drug molecules include physicochemical aspects of the 
drug, such as log P, pKa, solubility and molecular mass.[12–14] For an 
API to be effective when applied topically, the API molecules must 
have a size <500 Da to enable diffusion across the SC, thereby pen-
etrating to the site of action.[2, 15] This molecular size consideration 
is also an aspect that can be challenging when developing topical 
formulations. Moreover, formulations must have aqueous and lipid 
solubility action.[12, 15] Patient individual variability regarding skin 
in both healthy and diseased skin may also influence the efficacy of 
API.[16] These unique variations are caused by biological factors and 
include skin hydration, gender, age, ethnicity and metabolism.[16, 17] 
For example, some enzymes in the skin may metabolize some drugs 
before cutaneous absorption can occur. Local skin irritation, such 
as irritant and allergic contact dermatitis, at the site of delivery can 
also pose a substantial challenge for topical applications.[18] Other 
disadvantages of topical formulations include being time-con-
suming to apply; the regimen can also be complicated, messy and 
uncomfortable.
Two mechanisms of vesicle absorption have been proposed 
for transdermal vesicular drug delivery, viz. the diffusion of intact 
vesicles through the SC and the formation of new vesicles from in-
dividual components of the formulation.[19] The latter phenomenon 
occurs only in certain regions within the SC, specifically where 
water content is high. This phenomenon is highly postulated since 
the vesicles' diameter is greater than the lamellar spaces of the lipid 
within the SC.[19]
In humans, liposomes have shown to be superior in delivering 
methotrexate and refining its activity for transport resistant leukemic 
cell lines compared to non-entrapped methotrexate formulations.[20] 
A dual deformable liposomal ointment has also been used to suc-
cessfully penetrate retinoic acid and epidermal growth factor to en-
hance healing in burn wounds.[21] In the cosmetic industry, liposomal 
and niosomal formulations containing urea were manufactured for 
use.[22] The optimized niosomal formulation was the best moistur-
izing dermato-cosmetic, while the optimized liposomal formulation 
also outperformed the conventional formulation.[22] In an attempt to 
treat pattern baldness, minoxidil was incorporated into niosomes. 
The study revealed that the niosomal formulations of minoxidil im-
proved follicular delivery by substantially increasing the partition of 
minoxidil in the aqueous canal of the human hair.[23] In dolor treat-
ment, the selective cyclooxygenase-2 (COX-2) inhibitor, nimesulide, 
was successfully encapsulated into niosomes for transdermal delivery 
and exhibited enhanced anti-inflammatory properties when com-
pared to delivery of nimesulide from conventional technologies.[24]
Similarly, the non-steroidal inflammatory drug ketorolac was suc-
cessfully entrapped in niosomes, significantly improving permeation 
and reducing the lag time post-application.[25] Niosomes formulated 
using α-omega-hexadecyl-bis-(1-aza-18-crown-6) or Bola, Span 80 
and cholesterol in a 2 : 5 : 2 molar ratio were proposed as a suit-
able delivery system for 5-fluorouracil (5-FU) for use in therapy for 
various skin cancers. This formulation exhibited increased cytotoxic 
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Table 3 Summary of significant review manuscripts
Author(s)/year Aim Research method Key findings
Vitorino et al. (2015)[11] To investigate different methods of 
permeation enhancement by combining 




The majority of approaches commonly utilized 
in transdermal delivery of drugs have 
advantages and disadvantages; therefore, 
further research is required for efficient 
drug delivery. The skin barrier is considered 
a formidable obstacle for drug delivery; 
however, new multicomponent technologies 
have combined several strategies, which have 
been reported to provide promising results for 
drug delivery.
Haque and Talukder 
(2018)[13]
To review available knowledge related to 
the skin-chemical enhancer interaction 




Out of all approaches which can be utilized 
for enhancing penetration of drug molecules 
across the skin, chemical enhancers have been 
reported to have more efficiency due to their 
capability to improve molecule permeation.
Bolzinger et al. (2012)[12] To analyse the mechanism of penetration 
of drugs through the skin.
Secondary 
qualitative review
Due to the heterogeneous structure of the skin, 
there are a number of penetration routes. The 
analysis of penetration mechanisms reveals 
that controlling the intercellular penetration 
route using crystalline lipids, and penetration 
via skin appendages, are likely contributors of 
efficient drug penetration. 
Benson et al. (2019)[14] To discuss the evolution of the principles 
of percutaneous absorption and skin 
products from recent times to date.
Secondary 
qualitative review
Skin application products range from simple 
solutions and ointments to nanotechnologies. 
However, the products applied to the skin for 
cosmetic or for treatment purpose must fulfil 
safety requirements.
Singh and Morris (2011)[16] Analysis of biological factors that 
contribute to variations in transdermal 
permeation of drugs across human 
skin. Analysis of currently available 
transdermal therapeutic systems which 
might be efficient in reducing biological 
factors which cause variations.
Secondary 
qualitative review
There is a significant requirement to 
take preventive steps to avoid harmful 
generalizations when prescribing transdermal 
products. The patient information leaflet must 
always include specific instructions, including 
the application and duration of application.
Paudel et al. (2010)[18] To provide an overview of transdermal 
products presented within the market 
and in clinical trials, and to focus 
on the challenges and solutions for 
overcoming the problems of skin 
irritation and skin permeation.
Secondary 
qualitative review
The emergence of skin permeation enhancement 
techniques and reducing skin irritation 
would improve the transdermal market for 
macromolecules, hydrophilic compounds and 
conventional drugs.
Paolino et al. (2008)[26] To improve the cytotoxic drug effect 
towards various types of skin cancer 
cell lines by utilizing bola-niosomes. 
Experimental 
research
The research outcomes revealed that
technological features of bola-niosomes are 
encouraging and can be applied to treat a 
number of cancerous skin diseases.
Mohanty et al. (2018)[28] To focus on different aspects of 
ethosomes, such as their penetration 
mechanism, preparation, 
composition, advantages, application 




 Due to having malleable vesicles, ethosomal 
carriers provide new opportunities for 
developing novel improved therapies. 
However, at the same time, it is significant 
to deal with the challenges associated to 
ethosome-based therapies.
Wang et al. (2020)[31] To enhance the therapeutic efficiency of 
psoriasis based on trans-retinoic acid 
and betamethasone by formulating a 
dual-loaded flexible liposomal gel. 
Experimental 
research
The outcomes of the research revealed that the 
flexible dual-loaded liposomal gel provided 
a synergistic effect. This effect was found 
as an efficient topical therapy for psoriasis 
treatment.
Amnuaikit et al. (2018)[34]  To develop as well as to characterize 
phenylethyl resorcinol-loaded 




The elastic vesicle carriers, viz. invasomes and 
transferosomes were an appropriate delivery 
system for phenylethyl resorcinol, which has 
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of up 4-fold compared to conventional technologies.[26] Novel elastic 
niosomes using Tween 61 and ethanol were developed to enhance 
the transdermal delivery of diclofenac diethylammonium and the 
anti-inflammatory effect of the molecule.[27]
Ethanol-containing elastic vesicles interact with the lipid mol-
ecules in the skin resulting in an increased fluidity of the SC and a 
decrease in the density of the multiple lipid layers of cell membranes, 
thereby enhancing the inter- and intra-cellular permeability of the 
vesicles. The use of ethanol also improves the vesicular membrane's 
elasticity and facilitates entry of vesicles into the SC and deeper/in-
ward layers of the skin.[28, 29] An optimized ethosomal formulation 
for the delivery of lamivudine showed 25 times greater transdermal 
flux across rat skin than that of a lamivudine solution. Microscopic 
studies revealed that ethosomes reached the intercellular regions of 
the skin's deeper layers and ethosomes exhibited significantly higher 
intracellular uptake viz. 85.7% when compared to API solution viz. 
24.9%.[30] Flexible liposomes containing alcohol showed the best 
transdermal efficiency for encapsulated retinoic acid for psoriasis 
treatment through close contact with the surface of the skin and re-
duction of trans-epidermal water loss.[31]
Novel transferosomes were found to penetrate the skin's deep 
layers[28, 32] and reach the systemic circulation following topical ap-
plication. Transferosomes can spontaneously and easily penetrate 
the intact SC via the intracellular or trans-cellular routes of penetra-
tion due to their elastic nature. The latter is achieved by modification 
of the intercellular lipid lamellae, which in turn facilitates the pene-
tration of free API molecules.[33]
In a B16 melanoma cell model, transferosomes and invasomes 
exhibited more significant tyrosinase inhibition activity and melanin 
reduction than the liposomes.[34] The increased solubility, stability 
and skin permeation were corroborated in a study undertaken using 
calcein and carboxyfluorescein as the encapsulated API.[35]
Ocular
Ocular/opthalmic delivery is among the most promising yet chal-
lenging modes of drug delivery.[36] This challenge poses an excellent 
opportunity for the rational design of novel and significantly im-
proved ocular delivery systems. The main challenge of designing an 
effective drug delivery system is to achieve an optimally safe drug 
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high therapeutic efficacy. The natural distribution of aqueous humor 
and tear fluid decreases the contact time of topically delivered API. 
In addition, other ocular barriers in the corneal and conjunctival epi-
thelia and the retinal pigment epithelium hinder the transportation 
of drug molecules.[36, 37] These factors lead to low bioavailability of 
drugs from ocular therapy, and only a minute quantity of the drug is 
absorbed. It is estimated that only about 1–5% of the drug instilled 
into the eye is absorbed.[37, 38]
For certain drug molecules, regular instillation of eye drops is 
necessary to achieve and thus maintain a therapeutic concentration 
of API at the site of action or in the tear film. The periodic instilla-
tions are necessitated by the rapid elimination of the drug through 
blinking and tear flow, resulting in reduced therapeutic efficacy.[37] 
The frequent use of highly concentrated solutions to achieve the de-
sired therapeutic results may cause toxic effects and impairment of 
cells at the ocular surface. Consequently, the time of residence of 
the API in the tear film must be maximized to exert an efficacious 
and therapeutic local effect. Moreover, reduced dosing of ocular 
preparations may enhance patient adherence. Therefore, ocular de-
livery systems such as polymeric inserts, aqueous gels, emulsions, 
suspensions, ointments and viscous solutions have been developed 
to maximize the bioavailability of API delivered via the aforemen-
tioned route.[39, 40]
Micro- and nano-particulate delivery systems are utilized to im-
prove the residence time of drug molecules on ocular surfaces via 
the interaction of functional groups and surface charges of these 
systems with the mucin layer, ultimately prolonging the interaction 
of the formulation at the corneal surface.[41, 42] Entrapment of API 
into nanoparticles to shield them from degradation by enzymes has 
successfully been achieved. Consequently, this approach permits re-
duced doses to attain therapeutic efficacy and prevents undesirable 
side effects.[42, 43]
Dai et al.[44] investigated liposomes for ophthalmic delivery. The 
authors used liposomes containing bile salts to deliver tacrolimus in 
an attempt to improve corneal permeability. Liposomes synthesized 
with sodium taurocholate and sodium glycocholate were postu-
lated as viable API carriers in ocular delivery. This was attributed 
to low toxicity and improved permeability. Non-toxic liposomal 
formulations containing minocycline designed for ocular use were 
found to deliver 40% of the API to the retina post-sub-conjunctival 
injection.[45]
The delivery of timolol maleate in niosomes appeared to be 
better than using conventional delivery approaches for timolol.[46] 
Studies involving the delivery of gentamycin and pilocarpine as 
niosomal formulations revealed a better pharmacodynamic response 
than when conventional delivery technologies were used.[47–49] 
Multilamellar niosomes showed to be a promising carrier for ocular 
delivery of acetazolamide. In vivo characterization of these niosomes 
revealed a considerable reduction in intraocular pressure compared 
to a simple solution of acetazolamide.[50]
Novel Spanlastics were manufactured to overcome the chal-
lenges associated with fluconazole and decrease the toxicity levels 
observed when a fluconazole solution was administered. The VDDS 
did not exhibit any cytotoxic effects and showed a tripled increase in 
ocular permeability compared to the commercially available Zocon 
(fluconazole, 0.3% w/v) formulation.[51]
Transungual drug delivery systems
Diseases that affect the human nail range from mild pigmenta-
tion due to smoking to more severe infections and inflammation. 
Onychomycosis and nail psoriasis are the most common.[52, 53] 
Historically, nail disorders have been treated using a combination 
of systemic antifungals or local antimycotics, steroids or vitamins.[54] 
Systemic therapies to treat nail disorders are associated with inci-
dences of systemic side effects and drug interactions. This challenge 
can be resolved by topical transungual drug delivery systems.[55]
The nails' horny structure is the main challenge with regards to 
topical drug delivery. The compact, highly keratinized nail plate hin-
ders drug permeability and uptake into the nail(s). The stable di-
sulfide bonds in the nail plate are responsible for causing the nail's 
hardness and, in turn, restricts the penetration of the drugs.[56] The 
low permeability and poor drug uptake can be attributed to the nail 
plate structure, composed of compact keratin molecules with disul-
fide bonds. Together, they are responsible for the hardness of the nail 
and provide a significant barrier to drug permeation.[56, 57]
Transungual delivery provides localized drug delivery, promotes 
patient compliance due to the technology's non-invasive nature and 
reduces systemic effects, potentially making it a cost-effective drug 
delivery approach.[52, 54] Despite the benefits of transungual drug de-
livery in treating nail disorders, the low permeability of topical drugs 
across the nail plate warrants further research and development into 
this technology.[54]
As alluded to above, transungunal drug delivery and drug effi-
cacy are related to the physicochemical properties of the drug mol-
ecule and the formulation characteristics.[58, 59] Targeting any of these 
parameters through physical or chemical techniques may improve 
the permeability, and consequently, the effectiveness of the drug.[53]
The physical techniques include reducing the nail thickness by 
filing, direct penetration of the nail plate and delivery of the drug via 
microporation, and disruption of the keratinized structure of the nail 
plate using laser energy or low-frequency ultrasound.[55, 60]
The chemical techniques used to improve transungual perme-
ability include using nail softeners such as urea, salicylic acid in 
combination with N-(2-mercaptopropionyl) glycine and water. 
These agents result in swelling and the formation of the pores in the 
nail plate, thus increasing the permeability of the drug. Drug perme-
ability may also be improved by breaking down the keratin-disulfide 
matrix of the nail plate using keratolytic enzymes and chemicals 
that cleave disulfide bonds such as N-(2-mercaptopropionyl) gly-
cine, N acetylcysteine, sodium sulfite and hydrogen peroxide.[52, 
60] Permeation enhancers, polyethylene glycols and inorganic salts 
such as sodium phosphate have been found to increase transungual 
drug permeation by moisturizing the nail plate, altering the keratin 
matrix and increasing thermodynamic activity of the API following 
interaction with an inorganic salt.[52, 60] The success of transungual 
therapy may also be increased by using large amounts of a drug 
molecule to maintain sufficient therapeutic drug concentrations and 
compensate for the loss of drug due to everyday activity, the extent 
of drug–keratin binding and clearance of the drug.[61]
Nanoparticles (NP) are among novel strategies to overcome 
challenges in transungual drug delivery.[52] As nanoparticles are 
smaller in size than other drug formulations, drugs formulated as 
nanoparticles easily diffuse through the keratin network as the per-
meability coefficient is increased with a decrease in the molecular 
size of diffusing molecules.[62] NP have found use in delivering tar-
geted antifungal therapy, permitting the release of concentrated API 
while maintaining a low administration dose. The increased dose at 
the site of action can wipe out the infecting fungi before developing 
resistance, thereby overcoming this vexing issue and improving the 
side effect profile.[63]
Liposomal and ethosomal formulations for transungual delivery 
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as the model API.[64] The outcomes of the study suggested that lipo-
somes and ethosomes could enhance penetration of hydrophilic sub-
stances through the nail plate, and both systems can be used for 
topical treatment of nail disorders.[64]
To date, topical therapy for onychomycosis with terbinafine 
hydrochloride (TBF-HCl) is non-existent. A  novel liposome film 
preparation containing TBF-HCI was made for simple and pain-
less application for an extended period on the nail plate to improve 
drug penetration through the nail plate. In addition, the adhesive 
properties of the technology were found to be adequate as a simpler 
topical treatment.[65] The aforementioned study developed a novel 
experimental animal model using Trichophyton mentagrophytes 
without using an immunosuppressed agent. In vivo investigations 
concluded that the TBF-HCl loaded liposome film preparation can 
be recommended as an auspicious system for ungual treatment of 
onychomycosis.[65]
Similarly, Ghannoum et al.[66] attempted to incorporate TBF into 
transferosomes to enhance the ability to treat onychomycosis. The 
results suggested that the potent inhibitory and fungicidal activity of 
TBF, combined with the ability of transferosomes to provide targeted 
drug delivery to the nail bed, could provide a potential clinically 
beneficial alternative for the treatment of onychomycosis.
Shah et  al.[67] conducted a study to encapsulate TBF-HCl into 
liposomes and subsequently load the liposomes into a nail lacquer. 
The results concluded that the permeation of TBF-HCl through 
the human nail plate was improved significantly when applied as 
a liposome-loaded preparation compared to TBF-HCl lacquer con-
taining a penetration enhancer.[67] Therefore, liposome-in-lacquer 
preparations can provide a more refined approach for transungual 
delivery which can ultimately be considered for administering API 
utilized explicitly in nail disorders.[67]
Novel Approaches to Vesicular Drug Delivery
Environmentally responsive dispersants
Recently, there has been enormous progress in drug delivery sub-
sequent to the discovery of liposomes and other VDDS. However, 
there is still a continued necessity for enhancements to fight the 
drawbacks exhibited by these delivery systems. The stability issue 
of liposomes and related vesicles remains an aspect that is encircled 
by various problems. Among which, the formation of ice crystals in 
liposomes,[68] physical and chemical instability of VDDS due to oxi-
dation of cholesterol and phospholipids,[68] and seepage of entrapped 
API.[69, 70] Pharmacosomes do not exhibit loss of drug leakage due 
to the covalent bod between the API and the phospholipids used in 
manufacture.[1, 8]
Several attempts have been proposed and undertaken to improve 
the stability of vesicles and enhance drug efficiency in lipid vesicles. 
The use of environmentally responsive dispersants (ERD) such as 
hydrogels have been shown to provide the best solution to tackle 
such challenges.[71, 72]
Thermo-responsive hydrogels
Thermosensitive hydrogel systems provide an opportunity to de-
liver a liquid solution or suspension containing a payload that, 
once administered, forms an in-situ gel at the site of administra-
tion when a specific target temperature is reached. These systems 
are injectable fluids that can be presented into the body in a min-
imally invasive way before gelling within the desired organ, tissue 
or body orifice. These gelling systems present numerous benefits 
compared to delivery technologies preshaped in their final form 
before insertion. For instance, injectable fluids do not require sur-
gical interventions for implantation or removal if non-biodegrad-
able materials are used. In addition, different therapeutic agents 
can be integrated using simple processes such as blending. When 
used to fill cavities or a flaw, their flowable nature ensures a per-
fect fit.[73]
Poly (N-isopropyl acrylamide) (pNIPAAM) is a polymer with 
thermosensitive properties. It displays a critical solution temperature 
at 32°C which may be offset to physiological values. This can be 
achieved by including surface active agents or polymers in the for-
mulation. These polymers display distinctive qualities with respect 
to the sharpness of an almost discontinuous transition and render 
pNIPAAM a suitable carrier to contemplate in situ gelling drug de-
livery. The gelation of 5% w/v polymer solutions occurs at different 
temperatures in phosphate-buffered saline (PBS). At 27°C, the trans-
parent solution becomes cloudy and eventually solidifies to form a 
gel on further heating.[74]
Triblock copolymers of polyethylene glycol-b-polypropylene 
glycol-b-polyethylene glycol (-PEO-PPO-PEO-), commercially avail-
able as grades of Pluronic or Poloxamer, are non-ionic, water-soluble 
materials that have been used as pharmaceutical excipients. The 
polymers are amphiphilic, display properties related to surfactants 
and are able to interact with biological membranes and hydrophobic 
surfaces.[75, 76]
Polypropylene glycol (PPO) forms a central hydrophobic core in 
which methyl groups interact via van der Waal's forces when sub-
stances undergo solubilization.[77–80] However, water solubility re-
sults from hydrogen bonds resulting from ether-oxygen and water 
molecules in the PEO block, making Poloxamers readily soluble in 
nonpolar organic solvents and useful for the formulation of novel 
dosage forms[78, 81] as aqueous solutions of Poloxamers dissolved in 
acids, alkalis and metal ions.[78]
Pluronic F127 (PF-127) gels are particularly favored as cell and 
API carriers because of their non-toxic property, reversible gelation, 
high entrapment capability and ability to form gels at physiological 
conditions when used at relatively low concentrations.[82–84] At con-
centrations ≥20% w/w, PF-127 solutions are liquid at or below room 
temperature but transform into viscous hydrogels at body tempera-
ture (37°C). The controlled release of pilocarpine,[82] oxytocin,[84] 
mitomycin C[83] and vancomycin[85] have been achieved using PF-127 
thermosensitive gels.
When coformulated with β-glycerophosphate, chitosan has also 
been used to produce thermosensitive hydrogels.[86–88] Han et al.[86] 
developed a formulation that exhibited a synergistic antitumour 
effect with doxorubicin and vaccinia virus vaccine expressing Sig/
E7/LAMP-1 as a chemo-immunotherapeutic agent. Chitosan 
β-glycerophosphate thermo-sensitive hydrogels have similarly been 
developed for the delivery of ellagic acid and mitomycin C for the 
treatment of brain cancer[88] and bladder cancer,[89] respectively. In 
addition, chitosan hydrogels have been used for transcorneal admin-
istration of 5-fluorouracil.[87]
An incorporation of nanovesicles and gels is known as nano-
composite gels. These nanocomposite gels have successfully been 
used in the delivery of various drugs for transdermal purposes such 
as loading of papain in elastic niosomes gels for the treatment of 
scars,[70] encapsulating loperamide in liposomal gels,[90] formulating 
ketoconazole in niosomal gels[91] and retinoic acid and betamethasone 
in flexible liposomal gels.[31] Nanocomposite gels have been used to 
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Thermosensitive polymeric systems avoid the use of toxic or-
ganic solvents. These materials can be used to deliver hydrophilic 
and lipophilic molecules with fewer systemic adverse effects while 
achieving targeted drug delivery with sustained-release attributes. 
Despite these benefits, several disadvantages associated with the 
use of these systems have been highlighted, which include an initial 
high-burst release, the low mechanical strength of gels resulting in 
possible dose-dumping, the absence of biocompatibility of polymers 
and a slow pH reduction of the system due to degradation in acidic 
environments.[73, 93]
pH-responsive hydrogels
The composition of all pH-sensitive polymers is consistent and com-
prises of acidic or basic functional groups. These groups can either 
accept or release a proton due to changes to the pH of the sur-
rounding. Polymers with several ionizable groups or polyelectrolytes 
can be classified as weak polyacids or polybases. Weak polyacids are 
proton acceptors at low pH values and discharge protons at neutral 
and high pH.[94] Poly(acrylic acid) (PAAc) and poly(methacrylic acid) 
(PMAAc) are commonly used pH-responsive polyacids.[95, 96]
As the pH of the environment changes, acidic groups undergo 
ionization at a specific pH corresponding to the pKa of the com-
pound. The swift shift in the net charge of the connected group re-
sults in a change of the molecular structure of the polymeric chain, 
and the transition to an expanded state is facilitated by osmotic 
pressure from available mobile counter ions, neutralized by network 
charges.[97]
It is cardinal to select a polymer with a pH that matches a target 
pH range when devising a successful pH-sensitive system. As an ini-
tial consideration, the pKa of the ionizable moieties in the polymer 
should possess the appropriate attributes for the intended applica-
tion. To achieve specific adaptation, the pH of the selected polymer 
can be modified by various strategies,[98] such as copolymerization 
with other polyelectrolytes or incorporation of a hydrophobic 
moiety into the backbone of the polymer. Though homopolymers 
of many polyelectrolytes exhibit pH-sensitivity, pH-dependent poly-
meric systems result from copolymerization to achieve greater con-
trol of system behaviour for a specific delivery system.[98]
Chitosan is a polycationic biopolymer soluble in acidic solu-
tion. It undergoes phase separation in the pH range close to neu-
trality through loss of a proton on the primary amino functional 
group.[97] The gelation mechanism of chitosan occurs through 
electrostatic attraction between the ammonium functional group 
of chitosan and inorganic ions, hydrogen bonding between the 
chitosan chains or hydrophobic chitosan–chitosan interactions. 
Nonetheless, the resultant gel demands additional cross-linking 
to produce a gel of adequate mechanical strength to release low 
molecular weight API in a controlled manner. The porosity of the 
chitosan gel that forms, which is dependent on the crystalline 
state of the chitosan used, is mainly responsible for the structural 
strength of chitosan gels.[97]
Ion-responsive hydrogels
The unique properties, biocompatibility, accessibility and cost-effect-
iveness have led to the use of natural gums for many daily applica-
tions. This class of compounds includes polysaccharides such as gum 
ghatti, gum acacia, guar gum, gum tragacanth and konjac gum. Agar 
gum, alginates and carrageenans are derived from seaweeds, while 
gellan gum, xanthan gum, rhamsan gum and welan gum are derived 
from microorganisms. Gums were mainly used as additives for food 
products.[99–101] However, natural gums or their derivatives have been 
studied as excipients for pharmaceutical or biomedical reasons[102] or 
matrix tablet production.[103–107]
Dual-stimuli responsive hydrogels
Chitosan-based materials have frequently been utilized in drug de-
livery for extended/sustained release of therapeutic agents.[108–111] 
Particularly, chitosan-based injectable gels, when combined with gly-
cerol, ethylene glycol and sorbitol, can deliver specific API at a target 
site.[112–114] The polyols maintain chitosan as a liquid, as they form a 
shield of water around the chitosan chains in an acidic solution to 
sustain its solubility at higher pH or at low temperatures.[109, 115] In 
addition, the use of β-glycerophosphate (β-GP) in combination with 
chitosan has been documented for applications in thermo-sensitive 
gel delivery.[116–118] Several interactions have been implicated during 
the gelation process, such as the loss of electrostatic repulsion and 
hydrogen bonding and increased hydrophobic interactions.
The increase in pH associated with the addition of β-GP to a 
solution of chitosan results in a reduction in electrostatic repulsion 
between chitosan chains. This promulgates an increment in inter-
chain hydrogen bonding. Furthermore, increasing the temperature 
releases hydrogen bonds between water molecules and chitosan 
chains, permitting increased hydrophobic interactions between 
chitosan chains.[109, 117–119]
Drug delivery using micro- and nano-scale hydrogels has been 
successful due to the biocompatibility and flexibility of physico-
chemical properties in addition to the protection of API in harsh en-
vironments. The high water content of the hydrogels permits stealth 
activity and increased circulation time by avoiding detection and 
evasion of an immune response in the patient.[120–122] The delivery 
of antioxidants or sunscreens to melanocytes in deep skin tissues 
to protect effects against melanin and freckles production may be 
achieved using dual-stimuli pH- and temperature-sensitive liposomal 
gels.[123]
Ionic liquids
Ionic liquids (IL) are commonly defined as salts composed solely of 
ions, with a melting point below 100°C.[124, 125] The formation of IL 
from API that are salts has a long history, as liquid formulations 
avoid polymorphism present in crystalline forms and tend to pro-
mote dissolution into water, leading to higher bioavailability.[125] 
There has been an imperative requirement for novel scientific ad-
vances that generate pioneering and efficient drug therapies in re-
cent years. The traditional strategies presently being pursued are 
attaining a stage at which it is challenging to develop new chemical 
entities that are efficacious. It is estimated that fewer than 10% of 
API currently evaluated in clinical trials attain market registration. 
This dramatically decreases the availability of effective medicaments 
for individuals in need.[126] Approximately 50% of all existing API 
are administered as salts. By pairing various counterions, it is pos-
sible to finely modify the physicochemical and biopharmaceutical 
properties of a given API. From a pharmaceutics perspective, the 
melting temperature and solubility are pertinent parameters from a 
drug processing and bioavailability point of view.[127]
Lipid phases have long been known to form within ionic liquids. 
One of the earliest reports of amphiphile self-assembly in ionic liquids 
is for βγ-distearoylphosphotidylcholine (DSPC) in ethylamonium ni-
trate (EAN), which forms a lamellar phase that shows similar tran-
sitions between ordered and gel phases as for DSPC in water.[128] 
Similarly, other lipids such as dipalmitoylphosphatidylethanolamine 
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water. DPPE formed 2D hexagonal phases in the IL, which were not 
seen for DDPE in water until very high temperatures, due to binding 
of the IL increasing the area per lipid head group.[129] However, the 
formation of vesicles in IL is less often reported but has been noted 
for phospholipids[130] and glycolipids.[131] The lipid bilayer in the ves-
icle must remain sufficiently flexible to maintain the spherical shape. 
The melting temperature of lipids depends on chain length, satur-
ation and interactions with the solvent. IL components with long 
hydrocarbon chains can insert into the bilayer membrane and lower 
Tm,
[130, 132] but may also alter membrane fluidity, curvature and thick-
ness, which may cause toxicity.[133]
Patra et al.[134] investigated the modulation of membrane prop-
erties by IL through monitoring the fluorescence of curcumin. Their 
research concluded that IL, which are extensively used in chemistry 
and have a bearing on human health, show a change in membrane 
properties. Long-chain IL resulted in a reduction in the phase transi-
tion temperature, and a higher molar ratio resulted in the fusion of 
solid-gel and liquid crystalline liposomal phases. Short chain IL had 
no significant influence on the phase transition temperature at molar 
ratios studied.[134]
Deep eutectic solvents
Deep eutectic solvents (DES) are a relatively novel solvents obtained 
by mixing organic compounds, resulting in a eutectic mixture. The 
melting point of the eutectic mixture is much lower than that of the 
individual constituents.[135] However, many liquids formed at non-
eutectic ratios are also referred to as DES. DES have been anticipated 
as promising alternatives to orthodox IL as they overcome various 
limitations of IL. Specifically, natural DES, which consists of nat-
ural origin components, are promising as solvents and dispersants 
for pharmaceutical use because they are biodegradable, possess a 
low toxicity profile, and can dissolve a variety of distinct chemical 
compounds. They have been used to dissolve poorly water-soluble 
compounds such as griseofulvin, danazol, benzoic acid, itraconazole, 
AMG517, rutin, cinnamic acid and taxol. Similarly, they have found 
applications in dissolving macromolecules such as DNA, starch, 
chitin and proteins.[136–140] Interestingly, dissolution in DES can also 
stabilize API against hydrolysis compared to dissolution in aqueous 
solutions.[141] In DES and DES/water mixtures, API has been incorpo-
rated into microemulsions as a transdermal drug delivery system.[142] 
DES is also known to improve skin penetration for compounds dis-
solved in them.[143, 144] DES may also be formed where one or both of 
the components are themselves API,[145] avoiding polymorphism in 
solid-phase mixtures.
In the context of bilayer drug delivery, vesicle formation in DES 
has been noted for several phospholipids[146–148] and glycolipids. The 
chain melting temperature of lipids is generally increased in DES 
compared to that for lipids in vesicles in water. Still, it is also de-
pendent on the hydrogen bond donor in the solvent.[147]
Conclusions
Topical drug delivery is a widely studied non-invasive route of ad-
ministration. Topical drug delivery systems offer an appropriate and 
ideal alternative route of administration to the traditional oral route 
of administration for several reasons: evading hepatic first-pass me-
tabolism, not requiring having a pleasant taste and circumventing 
gastrointestinal side effects. In addition, this drug delivery route al-
lows for steady drug plasma concentrations, improved adherence to 
therapy, reduced frequency of administration and degradation in the 
gastrointestinal tract. It avoids the possibility of over or under-dosing. 
Several effective drug molecules are available for topical disorders. 
However, physicochemical properties and undesirable toxicity pro-
files have limited their therapeutic efficacy. Vesicular delivery sys-
tems have the potential to overcome these shortcomings due to their 
unique attributes such as high biocompatibility, simplicity of sur-
face modification and suitability as vehicles for controlled delivery. 
However, incorporating these systems into environmentally respon-
sive dispersants such as hydrogels, ionic liquids and deep eutectic 
solvents may enhance therapeutic prowess of these delivery systems. 
Consequently, improved vesicular drug delivery can be achieved by 
considering combining some of these formulation approaches.
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